| 13.685 -1.185 (-7.97%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.77 |
1-year : | 19.08 |
| Resists | First : | 15.21 |
Second : | 16.34 |
| Pivot price | 14.69 |
|||
| Supports | First : | 13.39 |
Second : | 11.14 |
| MAs | MA(5) : | 14.9 |
MA(20) : | 14.8 |
| MA(100) : | 16.8 |
MA(250) : | 15  |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 27.4 |
D(3) : | 46.6 |
| RSI | RSI(14): 39.2 |
|||
| 52-week | High : | 21.5 | Low : | 9.65 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ MESO ] has closed above bottom band by 4.7%. Bollinger Bands are 27.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 14.01 - 14.08 | 14.08 - 14.14 |
| Low: | 13.24 - 13.31 | 13.31 - 13.37 |
| Close: | 13.58 - 13.69 | 13.69 - 13.79 |
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
Tue, 07 Apr 2026
Mesoblast drops after Ryoncil sales data for March quarter - Seeking Alpha
Tue, 07 Apr 2026
Mesoblast (MESO) Reports Strong Ryoncil Sales in Latest Quarter - gurufocus.com
Mon, 06 Apr 2026
Mesoblast (MESO) Reports Strong Ryoncil Sales Performance - gurufocus.com
Mon, 06 Apr 2026
Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter - The Manila Times
Mon, 06 Apr 2026
Mesoblast’s Ryoncil Achieves US$30.3 Million in Net Sales for March Quarter - Sharecafe
Wed, 01 Apr 2026
Mesoblast (MESO) CEO Silviu Itescu reports major share and option holdings - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 129 (M) |
| Held by Insiders | 8.5212e+008 (%) |
| Held by Institutions | 5 (%) |
| Shares Short | 2,690 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -6.434e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -144.4 % |
| Operating Margin | -55.2 % |
| Return on Assets (ttm) | -6.2 % |
| Return on Equity (ttm) | -18.3 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 619.76 |
| Sales Per Share | 7.69176e+007 |
| EBITDA (p.s.) | -2.73294e+007 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -60 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 25.84 |
| Dividend | 0 |
| Forward Dividend | 3.21e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|